GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Augmedix Inc (NAS:AUGX) » Definitions » Price-to-Free-Cash-Flow

Augmedix (Augmedix) Price-to-Free-Cash-Flow : N/A (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Augmedix Price-to-Free-Cash-Flow?

As of today (2024-05-17), Augmedix's share price is $1.20. Augmedix's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.44. Hence, Augmedix's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Augmedix's Price-to-Free-Cash-Flow or its related term are showing as below:

AUGX's Price-to-Free-Cash-Flow is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 17.6
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Augmedix's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.17. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.44.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 9.00% per year.

During the past 5 years, Augmedix's highest 3-Year average Free Cash Flow per Share Growth Rate was 9.00% per year. The lowest was 5.50% per year. And the median was 7.25% per year.


Augmedix Price-to-Free-Cash-Flow Historical Data

The historical data trend for Augmedix's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Augmedix Price-to-Free-Cash-Flow Chart

Augmedix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
- - - - -

Augmedix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Augmedix's Price-to-Free-Cash-Flow

For the Health Information Services subindustry, Augmedix's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Augmedix's Price-to-Free-Cash-Flow Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Augmedix's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Augmedix's Price-to-Free-Cash-Flow falls into.



Augmedix Price-to-Free-Cash-Flow Calculation

Augmedix's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=1.20/-0.436
=N/A

Augmedix's Share Price of today is $1.20.
Augmedix's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Augmedix  (NAS:AUGX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Augmedix Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Augmedix's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Augmedix (Augmedix) Business Description

Traded in Other Exchanges
N/A
Address
111 Sutter Street, Suite 1300, San Francisco, CA, USA, 94104
Augmedix Inc is engaged in ambulatory/clinical/hospital segments of the U.S. patient care services market with products that address medical note documentation needs. The company's products cater to large and small healthcare organizations but can also be adopted by individual practitioners. The company's revenues consist of service fees charged to its customers to subscribe to the company's remote medical documentation and clinical support products.
Executives
Paul Ginocchio officer: Chief Financial Officer C/O AUGMEDIX, INC., 111 SUTTER STREET, SUITE 1300, SAN FRANCISCO CA 94104
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Margie L. Traylor director 5130 E. CASCALOTE DR, CAVE CREEK AZ 85331
Redco Ii Master Fund, L.p. director, 10 percent owner ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Robert C. Faulkner director C/O REDMILE GROUP, ONE LETTERMAN DRIVE, BUILDING D, SUITE D, SAN FRANCISCO CA 94129
Roderick H. O'reilly director C/O CHANGE HEALTHCARE INC., 3055 LEBANON PIKE, SUITE 1000, NASHVILLE TN 37214
Mckesson Ventures, Llc director, 10 percent owner ONE POST STREET, SAN FRANCISCO CA 94104
William J Febbo director 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
Jonathan Hawkins officer: Chief Revenue Officer C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Sandra Breber officer: CHIEF OPERATING OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Ian Shakil officer: CHIEF STRATEGY OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Emmanuel Krakaris director, officer: PRESIDENT, CEO, AND SECRETARY C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Saurav Chatterjee officer: CHIEF TECHNOLOGY OFFICER C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103
Laurie Mcgraw director 4720 E COTTON GIN LOOP, SUITE 220, C/O MEDAVAIL HOLDINGS, INC., PHOENIX AZ 85040
Jason Krikorian director, 10 percent owner C/O AUGMEDIX, INC., 1161 MISSION STREET, SUITE LL, SAN FRANCISCO CA 94103